Loading data
IMONYSE
| Unit: CAD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 47.08 bn CAD | 51.53 bn CAD | 50.97 bn CAD | 59.67 bn CAD | 37.59 bn CAD |
| Research and development expense | 134 m CAD | 118 m CAD | 84 m CAD | 74 m CAD | 89 m CAD |
| Selling, general and administrative expense | 1.39 bn CAD | 945 m CAD | 857 m CAD | 882 m CAD | — |
| Interest expense | 12 m CAD | 41 m CAD | 69 m CAD | 60 m CAD | 54 m CAD |
| Profit before tax | 4.26 bn CAD | 6.24 bn CAD | 6.37 bn CAD | 9.48 bn CAD | 3.28 bn CAD |
| Income tax expense | 994 m CAD | 1.45 bn CAD | 1.48 bn CAD | 2.14 bn CAD | 804 m CAD |
| Net income (reported basis) | 3.27 bn CAD | 4.79 bn CAD | 4.89 bn CAD | 7.34 bn CAD | 2.48 bn CAD |
| Basic earnings per share | 6.5 CAD/share | 9.05 CAD/share | 8.51 CAD/share | 11.47 CAD/share | 3.48 CAD/share |
| Diluted earnings per share | 6.48 CAD/share | 9.03 CAD/share | 8.49 CAD/share | 11.44 CAD/share | 3.48 CAD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.